×
About 960 results

ALLMedicine™ Pure Red Cell Aplasia Center

Research & Reviews  236 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Jun 24th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Cancer in Inherited Bone Marrow Failure Syndromes
https://clinicaltrials.gov/ct2/show/NCT00027274

Jun 24th, 2022 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Incidence of Acquired Pure Red Cell Aplasia: A Nationwide Epidemiologic Analysis With 2...
https://doi.org/10.1182/bloodadvances.2021006486
Blood Advances; Nakazawa H, Sakai K et. al.

May 7th, 2022 - Acquired pure red cell aplasia (PRCA) is a rare syndrome characterized by anemia with reticulocytopenia and a marked reduction in erythroid precursors. Given its rarity, the true incidence is largely unknown, and epidemiological data representing ...

see more →

Drugs  112 results see all →

Clinicaltrials.gov  32 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Jun 24th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Cancer in Inherited Bone Marrow Failure Syndromes
https://clinicaltrials.gov/ct2/show/NCT00027274

Jun 24th, 2022 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Diamond Blackfan Anemia Registry (DBAR)
https://clinicaltrials.gov/ct2/show/NCT00106015

Apr 12th, 2022 - BACKGROUND: Diamond Blackfan anemia (DBA) is a heterogeneous genetic disorder characterized by pure red cell aplasia, congenital anomalies, a predisposition to pancytopenia and myelodysplasia as well as hematopoietic and non-hematopoietic cancer. ...

A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
https://clinicaltrials.gov/ct2/show/NCT00001962

Jul 9th, 2021 - Many bone marrow failure syndromes in humans are now recognized to result from immunological mechanisms. These diseases include aplastic anemia; single hematopoietic lineage failures such as pure red cell aplasia, Diamond Blackfan Anemia, agranulo...

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
https://clinicaltrials.gov/ct2/show/NCT04470804

Jul 7th, 2021 - Pure red cell aplasia (PRCA) is a rare normocytic normochromic anemia with reticulocytopenia, characterized by a reduction of erythroid precursors from the bone marrow, could be divided into congenital and acquired PRCA according to pathogenesis. ...

see more →

News  4 results

Brentuximab Vedotin in a Patient With Aggressive Systemic Mastocytosis and Pure Red Cell Aplasia
https://www.mdedge.com/fedprac/avaho/article/102811/lymphoma-plasma-cell-disorders/brentuximab-vedotin-patient-aggressive
Cooper K, Richter J et. al.

Sep 21st, 2015 - Backround: Mastocytosis is a rare disease with a variable clinical course. Pure red cell aplasia has not been frequently reported in association with aggressive systemic mastocytosis.

FDA: Peginesatide Noninferior to Existing EPO Agents
https://www.medpagetoday.com/hematologyoncology/anemia/30061

Dec 6th, 2011 - Peginesatide, an erythropoietin mimetic for treatment of anemia in chronic kidney disease (CKD) patients, appears to be noninferior to erythropoietin products but does raise some safety concerns when used in patients not on dialysis, according to ...

FDA Safety Changes: Actonel, Gardasil, Myfortic
https://www.medscape.com/viewarticle/708284

Sep 2nd, 2009 - This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. September 2, 2009 — The US Food and Drug Administration (...

FDA Safety Changes: Strattera, Aptivus, CellCept
https://www.medscape.com/viewarticle/707021

Aug 5th, 2009 - This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. August 5, 2009 — The US Food and Drug Administration (FDA...

see more →